Medication info
Foglomet SR Tablet 10/1000 mg

Foglomet SR Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, egg-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202106829 · Approved 2021.10.08

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin therapy, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood glucose control issues
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps control blood glucose levels in adult patients with type 2 diabetes through a combination of dapagliflozin and metformin. When used alongside diet and exercise, it can effectively manage blood glucose levels. It can also be administered to patients with cardiovascular disease or risk factors among those whose blood glucose is not adequately controlled. However, it is advisable to refer to professional materials for detailed information related to cardiovascular events. This medication is used for the treatment of type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no previous experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin therapy, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and aids in blood glucose control. There is a risk of a rare side effect called severe lactic acidosis when taking this medication, so caution is needed. Lactic acidosis can result in excessive buildup of lactic acid in the body and lead to a dangerous state, with symptoms including fatigue, muscle pain, difficulty breathing, and abdominal pain. Additionally, when taken along with insulin or sulfonylureas, there is a risk of hypoglycemia, so blood glucose levels should be checked regularly. This medication should not be administered to patients with impaired kidney function, dehydration, severe infections, heart issues, or liver dysfunction. Specifically, before and after tests that use iodinated contrast agents, this medication should be temporarily discontinued due to potential strain on the kidneys and should be resumed only after normal kidney function is confirmed. Women who are pregnant or breastfeeding should not take this medication and should stop immediately if pregnancy is planned or confirmed. Elderly patients or those with reduced kidney function should have their dosage adjusted and monitor kidney function regularly, taking special care if dehydrated or at risk of low blood pressure. It is important to frequently check fluid status, blood pressure, and kidney function while on this medication. This medication may cause side effects such as genital and urinary tract infections, headache, dizziness, gastrointestinal disturbances, muscle pain, among others, and if any unusual symptoms arise, consult a physician. Additionally, vitamin B12 levels may decrease, so regular blood tests to monitor this are advisable. Excessive alcohol consumption can increase the risk of side effects from this medication, so avoiding drinking is recommended. This medication may interact with other diabetes medications, blood pressure medications, diuretics, etc., so if you are taking other medications, you must inform your doctor or pharmacist. In case of overdose, seek medical attention immediately for appropriate treatment, and dialysis may be helpful if necessary. This medication is not recommended for use in children as its safety and efficacy have not been established. Finally, this medication should be stored out of reach of children and kept in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • sialadenoma
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periartritis
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a sealed container. It is important to maintain a temperature between 1–30 degrees Celsius to ensure the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Yellow, biconvex, egg-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.